“Australia’s policy change is one that every country should consider: suffering people, regardless of nationality, need more opportunities to access novel treatments,” MAPS founder and director Dr. …
After decades of criminalization, Australia’s government said Friday that it will legalize the prescription of MDMA and psilocybin for the treatment of two medical conditions, a historic move hailed …
Summary: “At this moment, when two successful Phase 3 studies of MDMA-assisted therapy for PTSD have brought us closer to potential FDA approval than ever before, MAPS and MAPS PBC must faithfully …
Summary: Technology Networks explores the rapid evolution seen in the world of science today, highlighting the potential benefits of psychedelic-assisted therapy. “The use of marijuana for medical …
In early January, MAPS announced that MAPP2 met pre-specified primary and key secondary endpoints and that it planned to file a new drug application submission in the third quarter of 2023. At the end …
Originally appearing here (Archived)
Summary: Founder and Executive Director of MAPS Rick Doblin discusses a new study that supports the psychedelic MDMA as treatment for PTSD on ‘Kennedy.’ Originally appearing here (Archived) …
Summary: Behavioral Health Business publishes an overview of the increasing popularity of psychedelics due largely to the promising psychedelic-assisted research results taking place. Author Laura Lovett …
Originally appearing here (Archived)
Originally appearing here (Archived)
Summary: Andrew Huberman, Ph.D., mentions MAPS and MAPS Founder and Executive Director Rick Doblin, Ph.D., while being interviewed by Tom Segura on the 2 Bears, 1 Cave (YMHstudios) podcast at 39 minutes …
Originally appearing here (Archived)
